Immediate Impact
1 from Science/Nature 52 standout
Citing Papers
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2024 Standout
Works of Martha Gonzalez being referenced
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
2023
Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Martha Gonzalez | 189 | 130 | 64 | 123 | 21 | 389 | |
| Hille Gieschen | 212 | 89 | 104 | 71 | 16 | 444 | |
| Kuen Chan | 190 | 123 | 83 | 35 | 19 | 445 | |
| M Sekiguchi | 81 | 69 | 41 | 125 | 27 | 390 | |
| Senthilmurugan Ramalingam | 194 | 268 | 63 | 59 | 13 | 429 | |
| Aruna Dontabhaktuni | 142 | 150 | 213 | 50 | 16 | 453 | |
| James A. Straw | 40 | 86 | 105 | 62 | 22 | 413 | |
| Andrew K. Kwegyir‐Afful | 182 | 241 | 50 | 61 | 12 | 381 | |
| Olaf Prien | 136 | 96 | 56 | 40 | 16 | 343 | |
| Monica Campagnoli | 75 | 307 | 47 | 53 | 39 | 448 | |
| Takenori Hitaka | 181 | 136 | 39 | 131 | 15 | 427 |
All Works
Loading papers...